We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Department of Medicine

You are here


Visceral Leishmaniasis: Immunoregulation of Host Response to Antileishmanial Chemotherapy and Immunochemotherapy


Various host immunologic mechanisms, largely T [Th1] cell-dependent, regulate the in vivo capacity to respond to antileishmanial chemotherapy. Using pentavalent antimony and amphotericin B as two distinct pharmacologic probes in L. donovani-infected mice, this project examines the host mechanisms that determine or can enhance initial in-vivo host responsiveness to chemotherapy, and/or regulate subsequent prevention of posttreatment relapse. The work is focused on the interaction of antileishmanial chemotherapy with amplified cytokine-induced macrophage activation, chemokine-induced granuloma assembly, CD4 and CD8 cell responses, activating and deactivating mechanisms (cytokines, receptors, intracellular signaling), and immunologic effects induced by chemotherapy itself. The goal of the project is to employ immunochemotherapy to improve treatment-induced outcome in visceral leishmaniasis - both the initial host response to chemotherapy and the long-term prevention of relapse in this intracellular protozoal infection.

For nearly four decades, Dr. Murray has been working in the area of leishmaniasis (a tropical disease), both in the laboratory and clinically. For 15 years, he carried out clinical treatment trials research in visceral leishmaniasis ("kala-azar") in India. The drug he and colleagues in India introduced and tested for the treatment of kala-azar, miltefosine, was approved by the FDA in March 2014 as the first effective oral agent for leishmaniasis (visceral, cutaneous and mucosal infection).

Contact Information

Infectious Diseases

Roy M. Gulick, M.D., Chief

Avi Bueno, Administrator
Tel: (212) 746-4914
Fax: (212) 746-8675

Patient Appointments & Inquiries

Infectious Diseases Associates & Weill Cornell Travel Medicine
1305 York Avenue, Floor 4
New York, NY 10021
Tel: (646) 962-TRIP (8747)

Division Events

Division News

Division Publications

Clinical Trials

Related Internal Links

PDF icon Division Brochure
PDF icon Travel Clinic Brochure

Related External Links

Center for Special Studies
Clinical & Translational Science Center
Center for Global Health

Patient Care Links

Cornell Clinical Trials Unit
Weill Cornell Travel Medicine

Infectious Diseases Associates